+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Mexico Vaccine Market Report and Forecast 2025-2034

  • PDF Icon

    Report

  • 250 Pages
  • June 2025
  • Region: Mexico
  • Expert Market Research
  • ID: 6100926
The Mexico vaccine market was valued at USD 2.21 Billion in 2024, driven by the robust government immunization programs and innovations in vaccine technology in the region. The market is anticipated to grow at a CAGR of 5.30% during the forecast period of 2025-2034, with the values likely to reach USD 3.70 Billion by 2034.

Mexico Vaccine Market Overview

In Mexico, the vaccine market is witnessing significant growth, driven by the rising disease prevalence and increased government and private sector investment in immunization infrastructure. National programs, such as the National Vaccination Campaign against Influenza and COVID-19 (2024-2025), play a substantial role in boosting vaccine uptake, especially among vulnerable populations. Moreover, the increasing collaboration between government agencies and pharmaceutical companies is leading to improved vaccine delivery and storage, which is projected to positively impact the market dynamics.

Mexico Vaccine Market Growth Drivers

Rising Vaccine-Preventable Disease Incidence to Boost Market Growth

The increasing prevalence of infectious diseases is a major driver for the vaccine market in Mexico. It is reported that the country faces a significant burden from vaccine-preventable diseases. According to the World Health Organization (WHO), Mexico recorded 333,980 deaths from communicable, maternal, perinatal, and nutritional conditions in 2021, with 19,469 deaths attributed to infectious and parasitic diseases. Respiratory infections accounted for 292,606 deaths, as per the WHO Mortality Database. This rising disease incidence, especially among vulnerable groups such as the elderly and individuals with chronic conditions, is expected to augment the market demand in the coming years.

Mexico Vaccine Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Robust Regulatory Support

In September 2024, Mexico's Federal Commission for the Protection against Sanitary Risks (Cofepris) approved the Jynneos vaccine for use against Mpox in adults aged 18 and over. The vaccine is specifically intended for individuals at high risk of exposure and is not recommended for the general public, including children, pregnant women, or those who are breastfeeding. This regulatory approval reflects Mexico’s proactive public health strategy and is expected to contribute positively to the Mexico vaccine market growth.

Increasing Vaccination Campaigns

One of the key market trends is the rise in large-scale vaccination campaigns aimed at expanding vaccine coverage. For instance, the Ministry of Health’s (SSA) National Vaccination Campaign against Influenza and COVID-19 is set to run from October 15, 2024, to March 28, 2025, in Mexico. To achieve this, the SSA plans to distribute over 36 million doses of the influenza vaccine and about 23 million COVID-19 vaccine doses. Such public health initiatives are anticipated to elevate the Mexico vaccine market value in the forecast period.

Mexico Vaccine Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product Type

  • Multivalent Vaccines
  • Monovalent Vaccines

Market Breakup by Type

  • Subunit Vaccines
  • Recombinant vaccines
  • Conjugate Vaccines
  • Toxoid vaccines
  • Inactivated
  • Live Attenuated
  • mRNA vaccines
  • Viral vector vaccines

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Nasal

Market Breakup by Disease Indication

  • Viral Diseases
  • Hepatitis
  • Influenza
  • HPV
  • MMR
  • Rotavirus
  • Herpes Zoster
  • COVID-19
  • Others
  • Bacterial Vaccines
  • Meningococcal Diseases
  • Pneumococcal diseases
  • DPT
  • Others
  • Cancer Vaccines
  • Allergy Vaccines

Market Breakup by Age

  • Pediatric
  • Adult

Market Breakup by End User

  • Hospital Pharmacies
  • Retail Pharmacies
  • Government Suppliers
  • Others

Mexico Vaccine Market Share

Segmentation by Product Type Set to Hold High Market Value

Based on the product type, the vaccine market in Mexico is segmented into multivalent and monovalent vaccines. The multivalent vaccine segment is likely to hold a dominant market share owing to its efficiency, cost-effectiveness, and ease of administration. These vaccines reduce the number of injections needed, improving compliance, especially in pediatric and elderly populations. Multivalent vaccines such as the DTP (diphtheria, tetanus, pertussis), MMR (measles, mumps, rubella), and pentavalent vaccines are widely administered as part of the National Immunization Program in the country.

Mexico Vaccine Market Analysis by Region

In Mexico, the market dynamics vary significantly across different regions, influenced by factors such as healthcare infrastructure, population density, and public health initiatives. The central region, including Mexico City and Estado de México, is expected to lead the market share, owing to the high population density, advanced healthcare infrastructure, and the presence of key government health institutions. Additionally, high vaccination coverage in this region is driven by robust public health campaigns, including seasonal vaccinations like flu and COVID-19.

Leading Players in the Mexico Vaccine Market

The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

GlaxoSmithKline plc

GSK is a key player in advancing immunization coverage across Mexico, particularly through its focus on public-private partnerships and community-level health initiatives. The company supports Mexico’s vaccination goals by introducing next-generation vaccines. GSK is also actively involved in educational outreach, working alongside healthcare providers to boost awareness around preventable diseases.

Merck & Co.

Merck has a strong presence in the Mexico vaccine market. It delivers high-quality vaccines and supports evidence-based health initiatives. Merck's HPV vaccine is widely used to reduce cervical cancer rates, particularly through school-based immunization programs. The company collaborates with Mexican researchers and institutions to strengthen local clinical trial networks.

Sanofi

Sanofi is known for playing a prominent role in making immunization more inclusive and accessible throughout Mexico. The company works closely with public health agencies to improve childhood vaccination rates in both urban and remote regions. Sanofi also actively contributes to pandemic preparedness by supporting influenza surveillance systems in Mexico.

Pfizer Inc

Pfizer Inc., a global biopharmaceutical company, supports nationwide immunization strategies with its pneumococcal and meningococcal vaccines. The company collaborates with healthcare professionals to train staff in vaccine administration and improve cold chain logistics. To support equitable access, Pfizer partners with local and regional health authorities to facilitate distribution outreach programs and mobile vaccination units.

Other key players in the market include AstraZeneca plc and Johnson & Johnson Services, Inc

Key Questions Answered in the Mexico Vaccine Market Report

  • What was the Mexico vaccine market value in 2024?
  • What is the Mexico vaccine market forecast outlook for 2025-2034?
  • What is the market segmentation based on product type?
  • What is the market segmentation based on type?
  • What is the market breakup based on the route of administration?
  • What is the market breakup by disease indication?
  • What is the market breakup by age?
  • What is the market breakup by end user?
  • What major factors aid the Mexico vaccine market demand?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the major drivers, opportunities, and restraints in the market?
  • What are the major trends influencing the market?
  • Who are the key players involved in the Mexico vaccine market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Vaccine Market Overview
3.1 Latin America Vaccine Market Overview
3.1.1 Latin America Vaccine Market Historical Value (2018-2024)
3.1.2 Latin America Vaccine Market Forecast Value (2025-2034)
3.2 Mexico Vaccine Market Overview
3.2.1 Mexico Vaccine Market Historical Value (2018-2024)
3.2.2 Mexico Vaccine Market Forecast Value (2025-2034)
4 Mexico Vaccine Market Landscape*
4.1 Mexico Vaccine Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Mexico Vaccine Market: Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Type
4.2.3 Analysis by Route of Administration
4.2.4 Analysis by Disease Indication
4.2.5 Analysis by Age
5 Mexico Vaccine Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 PESTEL Analysis
5.3.1 Political
5.3.2 Economic
5.3.3 Social
5.3.4 Technological
5.3.5 Legal
5.3.6 Environment
5.4 Porter’s Five Forces Model
5.4.1 Bargaining Power of Suppliers
5.4.2 Bargaining Power of Buyers
5.4.3 Threat of New Entrants
5.4.4 Threat of Substitutes
5.4.5 Degree of Rivalry
5.5 Key Demand Indicators
5.6 Key Price Indicators
5.7 Industry Events, Initiatives, and Trends
5.8 Value Chain Analysis
6 Mexico Vaccine Market Segmentation (218-2034)
6.1 Mexico Vaccine Market (2018-2034) by Product Type
6.1.1 Market Overview
6.1.2 Multivalent Vaccines
6.1.3 Monovalent Vaccines
6.2 Mexico Vaccine Market (2018-2034) by Type
6.2.1 Market Overview
6.2.2 Subunit Vaccines
6.2.2.1 Recombinant vaccines
6.2.2.2 Conjugate Vaccines
6.2.2.3 Toxoid vaccines
6.2.3 Inactivated
6.2.4 Live Attenuated
6.2.5 mRNA vaccines
6.2.6 Viral vector vaccines
6.3 Mexico Vaccine Market (2018-2034) by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.3 Parenteral
6.3.4 Nasal
6.4 Mexico Vaccine Market (2018-2034) by Disease Indication
6.4.1 Market Overview
6.4.2 Viral Diseases
6.4.2.1 Hepatitis
6.4.2.2 Influenza
6.4.2.3 HPV
6.4.2.4 MMR
6.4.2.5 Rotavirus
6.4.2.6 Herpes Zoster
6.4.2.7 COVID-19
6.4.2.8 Others
6.4.3 Bacterial Vaccines
6.4.3.1 Meningococcal Diseases
6.4.3.2 Pneumococcal diseases
6.4.3.3 DPT
6.4.3.4 Others
6.4.4 Cancer Vaccines
6.4.5 Allergy Vaccines
6.5 Mexico Vaccine Market (2018-2034) by Age
6.5.1 Market Overview
6.5.2 Pediatric
6.5.3 Adult
6.6 Mexico Vaccine Market (2018-2034) by End User
6.6.1 Market Overview
6.6.2 Hospital Pharmacies
6.6.3 Retail Pharmacies
6.6.4 Government Suppliers
6.6.5 Others
7 Regulatory Framework
8 Patent Analysis
8.1 Analysis By Drug Type of Patent
8.2 Analysis by Publication Year
8.3 Analysis by Issuing Authority
8.4 Analysis by Patent Age
8.5 Analysis by CPC Analysis
8.6 Analysis by Patent Valuation
8.7 Analysis by Key Players
9 Clinical Trials Analysis
9.1 Analysis by Trial Registration Year
9.2 Analysis by Trial Status
9.3 Analysis by Trial Phase
9.4 Analysis by Therapeutic Area
9.5 Analysis by Geography
10 Funding and Investment Analysis
10.1 Analysis by Funding Instances
10.2 Analysis by Drug Class of Funding
10.3 Analysis by Funding Amount
10.4 Analysis by Leading Players
10.5 Analysis by Leading Investors
10.6 Analysis by Geography
11 Strategic Initiatives
11.1 Analysis by Partnership Instances
11.2 Analysis by Drug Class of Partnership
11.3 Analysis by Leading Players
11.4 Analysis by Geography
12 Supplier Landscape
12.1 GlaxoSmithKline plc
12.1.1 Financial Analysis
12.1.2 Product Portfolio
12.1.3 Demographic Reach and Achievements
12.1.4 Company News and Development
12.1.5 Certifications
12.2 Merck & Co.
12.2.1 Financial Analysis
12.2.2 Product Portfolio
12.2.3 Demographic Reach and Achievements
12.2.4 Company News and Development
12.2.5 Certifications
12.3 Sanofi
12.3.1 Financial Analysis
12.3.2 Product Portfolio
12.3.3 Demographic Reach and Achievements
12.3.4 Company News and Development
12.3.5 Certifications
12.4 Pfizer Inc.
12.4.1 Financial Analysis
12.4.2 Product Portfolio
12.4.3 Demographic Reach and Achievements
12.4.4 Company News and Development
12.4.5 Certifications
12.5 AstraZeneca plc
12.5.1 Financial Analysis
12.5.2 Product Portfolio
12.5.3 Demographic Reach and Achievements
12.5.4 Company News and Development
12.5.5 Certifications
12.6 Johnson & Johnson Services, Inc.
12.6.1 Financial Analysis
12.6.2 Product Portfolio
12.6.3 Demographic Reach and Achievements
12.6.4 Company News and Development
12.6.5 Certifications
13 Mexico Vaccine Market - Distribution Model (Additional Insight)
13.1 Overview
13.2 Potential Distributors
13.3 Key Parameters for Distribution Partner Assessment
14 Key Opinion Leaders (KOL) Insights (Additional Insight)

Companies Mentioned

  • GlaxoSmithKline plc
  • Merck & Co.
  • Sanofi
  • Pfizer Inc.

Table Information